BEONE MEDICINES (06160) has unveiled its interim results for the six months ended June 30, 2026, posting a net profit of $464 million, a substantial year-on-year increase of 385.8%.

The company's total revenue for the period reached $3.219 billion, marking a 32.3% growth compared to the same timeframe last year, with basic earnings per share coming in at $0.32.

During the second quarter of 2026, global revenue climbed 30% year-over-year to $1.7 billion. Sales of the globally marketed product BRUKINSA® (zanubrutinib) surged 31% from the second quarter of 2025, hitting $1.2 billion. On a GAAP basis, diluted earnings per American Depositary Share (ADS) stood at $2.05, while non-GAAP diluted earnings per ADS reached $3.84.

The 32.3% revenue increase for the first half of 2026 was primarily driven by higher sales of the company's proprietary products, BRUKINSA® and TEVIMBRA®, alongside increased revenue from Amgen-licensed products. Net product revenue grew 31.4% year-over-year, fueled mainly by BRUKINSA®'s global sales expansion, with sustained growth momentum coming from the U.S. and European markets.

Additionally, during the first six months of 2026, sales of TEVIMBRA® and Amgen-licensed products, particularly XGEVA®, also contributed positively to overall product revenue. The business model remains sustainable, underpinned by a robust global financial position.

The company believes it is in a solid financial state, holding cash and cash equivalents of $5.1 billion as of June 30, 2026. For the first half of 2026, product revenue, including the current portfolio and core products, increased 31.4% year-over-year, and management anticipates significant further growth in product revenue through the second half of 2026 and beyond.

GAAP net profit and non-GAAP net profit for the first half of 2026 improved further to $464 million and $820 million, respectively. Cash generated from operating activities remained consistently positive, with free cash flow reaching $596 million during the period.

The company intends to continue deploying capital cautiously and strategically, while pursuing partnership opportunities that can strengthen its operations, following its established collaboration model. Management remains committed to generating long-term value for shareholders.